MovDisordV3, PascalFrancis, Curation, bibRecord, 002581

Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?

Identifieur interne : 002581 ( PascalFrancis/Curation ); précédent : 002580; suivant : 002582

Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?

Auteurs : Morvarid Karimi [États-Unis] ; Stephen M. Moerlein [États-Unis] ; Tom O. Videen [États-Unis] ; Robert R. Luedtke [États-Unis] ; Michelle Taylor [États-Unis] ; Robert H. Mach [États-Unis] ; Joel S. Perlmutter [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:11-0143221

Descripteurs français

Pascal (Inist)
- Dystonie, Pathologie du système nerveux, Récepteur dopaminergique, Dopamine, Récepteur dopaminergique D2, Récepteur dopaminergique D3, Tomoscintigraphie, Tomographie par émission de positons.

English descriptors

KwdEn :
- D2 Dopamine receptor, D3 Dopamine receptor, Dopamine, Dopamine receptor, Dystonia, Emission tomography, Nervous system diseases, Positron emission tomography.

Abstract

Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular, dysfunction of D2-like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [¹⁸F]spiperone, a nonselective D2-like radioligand with nearly equal affinity for serotonergic 5-HT(2A) sites. We then repeated the study with [¹⁸F]N-methyl-benperidol (NMB), a more selective D2-like receptor radioligand with minimal affinity for 5-HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. The analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200-fold difference in affinity), whereas spiperone has similar affinity for all three of the D2-like receptor subtypes. These findings when coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?`
A11	`01`	`1`		`@1 KARIMI (Morvarid)`
A11	`02`	`1`		`@1 MOERLEIN (Stephen M.)`
A11	`03`	`1`		`@1 VIDEEN (Tom O.)`
A11	`04`	`1`		`@1 LUEDTKE (Robert R.)`
A11	`05`	`1`		`@1 TAYLOR (Michelle)`
A11	`06`	`1`		`@1 MACH (Robert H.)`
A11	`07`	`1`		`@1 PERLMUTTER (Joel S.)`
A14	`01`			`@1 Department of Neurology, Washington University School of Medicine @2 Saint Louis, Missouri @3 USA @Z 1 aut. @Z 3 aut. @Z 7 aut.`
A14	`02`			`@1 Mallinckrodt Institute of Radiology, Washington University School of Medicine @2 Saint Louis, Missouri @3 USA @Z 2 aut. @Z 3 aut. @Z 6 aut. @Z 7 aut.`
A14	`03`			`@1 Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine @2 Saint Louis, Missouri @3 USA @Z 2 aut. @Z 6 aut.`
A14	`04`			`@1 Department of Pharmacology and Neuroscience, University of North Texas Health Science Center @2 Fort Worth, Texas @3 USA @Z 4 aut. @Z 5 aut.`
A14	`05`			`@1 Department of Cell Biology and Physiology, Washington University School of Medicine @2 Saint Louis, Missouri @3 USA @Z 6 aut.`
A14	`06`			`@1 Department of Neurobiology, Washington University School of Medicine @2 Saint Louis, Missouri @3 USA @Z 7 aut.`
A14	`07`			`@1 Department of Occupational Therapy, Washington University School of Medicine @2 Saint Louis, Missouri @3 USA @Z 7 aut.`
A14	`08`			`@1 Department of Physical Therapy, Washington University School of Medicine @2 Saint Louis, Missouri @3 USA @Z 7 aut.`
A20				`@1 100-106`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000193724410140`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 71 ref.`
A47	`01`	`1`		`@0 11-0143221`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular, dysfunction of D2-like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [¹⁸F]spiperone, a nonselective D2-like radioligand with nearly equal affinity for serotonergic 5-HT(2A) sites. We then repeated the study with [¹⁸F]N-methyl-benperidol (NMB), a more selective D2-like receptor radioligand with minimal affinity for 5-HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. The analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200-fold difference in affinity), whereas spiperone has similar affinity for all three of the D2-like receptor subtypes. These findings when coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17H`
C03	`01`	`X`	`FRE`	`@0 Dystonie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dystonia @5 01`
C03	`01`	`X`	`SPA`	`@0 Distonía @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 09`
C03	`03`	`X`	`ENG`	`@0 Dopamine receptor @5 09`
C03	`03`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 09`
C03	`04`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 10`
C03	`04`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 10`
C03	`04`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 10`
C03	`05`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 11`
C03	`05`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 11`
C03	`05`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 11`
C03	`06`	`X`	`FRE`	`@0 Récepteur dopaminergique D3 @5 12`
C03	`06`	`X`	`ENG`	`@0 D3 Dopamine receptor @5 12`
C03	`06`	`X`	`SPA`	`@0 Receptor dopaminérgico D3 @5 12`
C03	`07`	`X`	`FRE`	`@0 Tomoscintigraphie @5 13`
C03	`07`	`X`	`ENG`	`@0 Emission tomography @5 13`
C03	`07`	`X`	`SPA`	`@0 Tomocentelleografía @5 13`
C03	`08`	`X`	`FRE`	`@0 Tomographie par émission de positons @5 14`
C03	`08`	`X`	`ENG`	`@0 Positron emission tomography @5 14`
C03	`08`	`X`	`SPA`	`@0 Tomografía emisión positrones @5 14`
C07	`01`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 37`
C07	`01`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`01`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`02`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`02`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie du muscle strié @5 39`
C07	`03`	`X`	`ENG`	`@0 Striated muscle disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Músculo estriado patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Trouble neurologique @5 41`
C07	`04`	`X`	`ENG`	`@0 Neurological disorder @5 41`
C07	`04`	`X`	`SPA`	`@0 Trastorno neurológico @5 41`
C07	`05`	`X`	`FRE`	`@0 Catécholamine @5 42`
C07	`05`	`X`	`ENG`	`@0 Catecholamine @5 42`
C07	`05`	`X`	`SPA`	`@0 Catecolamina @5 42`
C07	`06`	`X`	`FRE`	`@0 Neurotransmetteur @5 43`
C07	`06`	`X`	`ENG`	`@0 Neurotransmitter @5 43`
C07	`06`	`X`	`SPA`	`@0 Neurotransmisor @5 43`
C07	`07`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 44`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 44`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 44`
C07	`08`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 45`
C07	`08`	`X`	`ENG`	`@0 Central nervous system disease @5 45`
C07	`08`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 45`
N21				`@1 094`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000737

Links to Exploration step

Pascal:11-0143221

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?</title>
<author><name sortKey="Karimi, Morvarid" sort="Karimi, Morvarid" uniqKey="Karimi M" first="Morvarid" last="Karimi">Morvarid Karimi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Moerlein, Stephen M" sort="Moerlein, Stephen M" uniqKey="Moerlein S" first="Stephen M." last="Moerlein">Stephen M. Moerlein</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Videen, Tom O" sort="Videen, Tom O" uniqKey="Videen T" first="Tom O." last="Videen">Tom O. Videen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Luedtke, Robert R" sort="Luedtke, Robert R" uniqKey="Luedtke R" first="Robert R." last="Luedtke">Robert R. Luedtke</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center</s1>
<s2>Fort Worth, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Taylor, Michelle" sort="Taylor, Michelle" uniqKey="Taylor M" first="Michelle" last="Taylor">Michelle Taylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center</s1>
<s2>Fort Worth, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mach, Robert H" sort="Mach, Robert H" uniqKey="Mach R" first="Robert H." last="Mach">Robert H. Mach</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Cell Biology and Physiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurobiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Occupational Therapy, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Physical Therapy, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0143221</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0143221 INIST</idno>
<idno type="RBID">Pascal:11-0143221</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000737</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002581</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?</title>
<author><name sortKey="Karimi, Morvarid" sort="Karimi, Morvarid" uniqKey="Karimi M" first="Morvarid" last="Karimi">Morvarid Karimi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Moerlein, Stephen M" sort="Moerlein, Stephen M" uniqKey="Moerlein S" first="Stephen M." last="Moerlein">Stephen M. Moerlein</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Videen, Tom O" sort="Videen, Tom O" uniqKey="Videen T" first="Tom O." last="Videen">Tom O. Videen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Luedtke, Robert R" sort="Luedtke, Robert R" uniqKey="Luedtke R" first="Robert R." last="Luedtke">Robert R. Luedtke</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center</s1>
<s2>Fort Worth, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Taylor, Michelle" sort="Taylor, Michelle" uniqKey="Taylor M" first="Michelle" last="Taylor">Michelle Taylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center</s1>
<s2>Fort Worth, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mach, Robert H" sort="Mach, Robert H" uniqKey="Mach R" first="Robert H." last="Mach">Robert H. Mach</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Cell Biology and Physiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurobiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Occupational Therapy, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Physical Therapy, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>D2 Dopamine receptor</term>
<term>D3 Dopamine receptor</term>
<term>Dopamine</term>
<term>Dopamine receptor</term>
<term>Dystonia</term>
<term>Emission tomography</term>
<term>Nervous system diseases</term>
<term>Positron emission tomography</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dystonie</term>
<term>Pathologie du   système nerveux</term>
<term>Récepteur dopaminergique</term>
<term>Dopamine</term>
<term>Récepteur dopaminergique D2</term>
<term>Récepteur dopaminergique D3</term>
<term>Tomoscintigraphie</term>
<term>Tomographie par émission de positons</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular, dysfunction of D2-like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [<sup>18</sup>
F]spiperone, a nonselective D2-like radioligand with nearly equal affinity for serotonergic 5-HT(2A) sites. We then repeated the study with [<sup>18</sup>
F]N-methyl-benperidol (NMB), a more selective D2-like receptor radioligand with minimal affinity for 5-HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. The analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200-fold difference in affinity), whereas spiperone has similar affinity for all three of the D2-like receptor subtypes. These findings when coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KARIMI (Morvarid)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MOERLEIN (Stephen M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VIDEEN (Tom O.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LUEDTKE (Robert R.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>TAYLOR (Michelle)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MACH (Robert H.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>PERLMUTTER (Joel S.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center</s1>
<s2>Fort Worth, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Cell Biology and Physiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurobiology, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Occupational Therapy, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Physical Therapy, Washington University School of Medicine</s1>
<s2>Saint Louis, Missouri</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>100-106</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000193724410140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>71 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0143221</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular, dysfunction of D2-like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [<sup>18</sup>
F]spiperone, a nonselective D2-like radioligand with nearly equal affinity for serotonergic 5-HT(2A) sites. We then repeated the study with [<sup>18</sup>
F]N-methyl-benperidol (NMB), a more selective D2-like receptor radioligand with minimal affinity for 5-HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. The analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200-fold difference in affinity), whereas spiperone has similar affinity for all three of the D2-like receptor subtypes. These findings when coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17H</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Distonía</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur dopaminergique D3</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>D3 Dopamine receptor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor dopaminérgico D3</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Tomographie par émission de positons</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Positron emission tomography</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du muscle strié</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>45</s5>
</fC07>
<fN21><s1>094</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002581 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002581 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:11-0143221
   |texte=   Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?

Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri